Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-03-25
2009-12-15
Nickol, Gary B (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S402000, C424S198100
Reexamination Certificate
active
07632802
ABSTRACT:
The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-suppressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells from bone marrow. More particularly, S100A8, S100A9, S100A12 and S100A8/A9 are administered to patients with lowered neutrophil blood concentrations.
REFERENCES:
patent: 4833074 (1989-05-01), Fagerhol et al.
patent: 5350687 (1994-09-01), Odink et al.
patent: 5702920 (1997-12-01), Odink et al.
patent: 5731166 (1998-03-01), Geczy et al.
patent: 5849528 (1998-12-01), Hillman et al.
patent: 5965122 (1999-10-01), Namen et al.
patent: 6015552 (2000-01-01), Watanabe et al.
patent: 6103497 (2000-08-01), Hillman et al.
patent: 6117989 (2000-09-01), Bandman et al.
patent: 2003/0003482 (2003-01-01), Halle et al.
patent: 2005/0288211 (2005-12-01), Tessier et al.
patent: 2007/0231317 (2007-10-01), Tessier et al.
patent: 19811047 (1999-04-01), None
patent: 0219400 (1987-04-01), None
patent: 1066834 (2001-01-01), None
patent: WO 97/34013 (1997-09-01), None
patent: WO 99/47561 (1999-09-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 2004/004770 (2004-01-01), None
Ryckman et al., J. Immunol., Mar. 15, 2003, 170(6):3233-3242.
Zimmer et al., Brain Res. Bull., 1995, 37(4):417-429.
Salama et al., Eur., J. Surg., Oncol., 2008, 34(4):357-364.
Devery et al., J. Immunol., 1994, 152:1888-1897.
Fidler I. J., Cancer Res., 1985, 45:4714-4726.
Nicastri et al., Int Conf AIDS. Jul. 7-12, 2002; 14: abstract No. MoPeB3201.
Aboulafia, Chest, 2000, vol. 117:1128-1145.
Kumar et al. “Dimeric S100A8 in human neutrophils is diminished after phagocytosis” 2001, Journal of Leukocyte Biology, 70:59-64.
Nisapakultorn et al. “Calprotectin expression in vitro by oral epithelial cells confers resistance to infection by porphyromonas gingivalis” 2001, Infection and Immunity, 69:4242-4247.
Passey et al. “S100A8:emerging functions and regulation” 1999, J. Leukocyte. Biol., 66(4):549-556.
Yang et al. << Proinflammatory properties of the human S100 protein S100A12 >>2001, J. Leukoc Biol. 69:986.
Aguiar-Passeti et al. “Epithelioid cells from foreign-body granuloma selectively express the calcium-binding protein MRP-14, a novel down-regulatory molecule of macrophage activation.” 1997, J. Leukoc. Biol. 62:852-858.
Barthe et al. “Identification of “cystic fibrosis protein” as a complex of two calcium-binding proteins present in human cells of myeloid origin.” 1991, Biochim. Biophys. Acta. 1096:175-177.
Brandtzaeg et al. “Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurance in various epithelia.” 1987, American Journal of Clinical Pathology 87:700-707.
Brandtzaeg et al. “The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces.” 1995, Adv. Exp. Muc. Immunol.. 371A:201-205.
Bruggen et al. “The molecular nature of the cystic fibrosis antigen (letter).” 1988, Nature, 331:570.
Buisman et al. “Effect of granulocyte colony-stimulating factor on the course of infection with gram-positive bacteria in mice during granulocytopenia induced by sublethal irradiation or cyclophosphamide.” 1996, J. Infect. Dis.,174:417-421.
Cornish et al. “S100 protein CP-10 stimulates myeloid cell chemotaxis without activation.” 1996, J. Cell. Physiol. 166:427-437.
Dale et al. “Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin.” 1985, American Journal of Clinical Pathology 84:24-34.
Dell'Angelica et al. “Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binidng protein from pig granulocytes.” 1994, J. Biol. Chem. 269:28929-28936.
Donato, R. “Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type.” 1999, Bioch. Biophys. Acta 1450:191-231.
Edgeworth et al. “Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells.” 1991, J. Biol. Chem. 266:7706-7713.
Frosch et al. “Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.” 2000, Arthritis. Rheum, 43:628-637.
Giorgi et al. “Antinociceptive effect of the calcium-binding protein MRP-14 and the role played by neutrophils on the control inflammatory pain.” 1998, J. Leukoc. Biol. 64:214-220.
Gottsch et al. “Calgranulin C has filariacidal and filariastatic activity.” 1999, Infect lmmun. 67:6631-6636.
Guignard et al. “Identification and characterization of a novel human neutrophil protein related to the S100 family.” 1995, Biochem. J. 309:395-401.
Harrison et al. “Oxidation regulates the inflammatory properties of the murine S100 protein S100A8.” 1999, J. Biol. Chem. 274:8561-8569.
Hashemi et al. “Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication.” 2001, AIDS, 15:441-449.
Hattorri et al. “Comparative study of the effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on generation and mobilization of neutrophils in cyclophosphamide-treated neutropenic mice.” 1996, In Vivo, 10:319-328.
Hitomi et al. “A novel calcium-binding protein in amniotic fluid, CAAF1: Its molecular cloning and tissue distribution.” 1996, J. Cell. Sci. 109:805-815.
Hofmann et al. “Rage mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulinpolypeptides.” 1999, Cell. 97:889-901.
Hunter et al. “High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14.” 1998, J. Biol. Chem. 273:12427-12435.
Ilg et al. “Amino acid sequence determination of human S100A12 (P6, calgranulin C, CGRP, CAAF1) by tandem mass spectrometry.” 1996, Biochem. Biophys. Res. Commun. 225:146-150.
Ivanov et al. “Enzyme-linked immunosorbent assay for human MRP-8/MRP-14 proteins and their quantitation in plasma of hematological patients.” 1996, Immunol. Lett. 49:7-13.
Jinquan et al. “Psoriasin: A novel chemotactic protein.” 1996, J. Invest. Dermatol., 107:5-10.
Kocher et al. “Functional chemotactic-factor CP-10 and MRP-14 are abundant in murine abscesses.” 1996, Infect. Immun. 64:1342-1350.
Koike et al. “Regulation of myeloid-specific calcium binding protein synthesis by cytosolic protein kinase.” 1992, Journal of Biochemistry 112:624-630.
Kojima et al. “Human gingival crevicular fluid contains MRP8 (S100A8) and MRP14 (S100A9), two calcium-binding proteins of the S100 family.” 2000, J. Dent. Res., 79:740-747.
Komada et al. “Novel specific chemotactic receptor for S100L protein on guinea pig eosinophils.” 1996, Biochem. Biophys. Res. Commun. 220:871-874.
Kunz et al. “Macrophage marker 27E10 on human keratinocytes helps to differentiate discoid lupus eryhematosus and Jessner's lymphocytic infiltration of the skin.” 1999, Eur. J. Dermatol. 9:107-110.
Lagasse et al. “Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation.” 1988, Mol. Cell. Biol. 8:2402-2410.
Lau et al. “A chemotactic S100 peptide enhances scavenger receptor and Mac-1 expression and cholesteryl ester accumulation in murine peritoneal macrophages in vivo.” 1995, J. Clin. Invest. 95:1957-19
Rouleau Pascal
Ryckman Carle
Tessier Philippe
Vandal Karen
Nickol Gary B
Ogilvy Renault LLP
Universite Laval
Xie Xiaozhen
LandOfFree
S100 protein as neutrophil activator for alleviating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S100 protein as neutrophil activator for alleviating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S100 protein as neutrophil activator for alleviating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112449